The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer

SIMPLE SUMMARY: Routine neoadjuvant therapy for resectable and borderline resectable pancreatic cancer is gaining popularity, but its true oncological benefit remains disputed. Whilst the genotypic and phenotypic heterogeneity of pancreatic cancer is becoming increasingly appreciated, there is curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Nahm, Christopher B., Turchini, John, Sahni, Sumit, Moon, Elizabeth, Itchins, Malinda, Arena, Jennifer, Chou, Angela, Colvin, Emily K., Howell, Viive M., Pavlakis, Nick, Clarke, Stephen, Samra, Jaswinder S., Gill, Anthony J., Mittal, Anubhav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367299/
https://www.ncbi.nlm.nih.gov/pubmed/35892879
http://dx.doi.org/10.3390/cancers14153620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367299/
https://www.ncbi.nlm.nih.gov/pubmed/35892879
http://dx.doi.org/10.3390/cancers14153620

Ejemplares similares